Echocardiographic Assessment of Cardiac Valvular Regurgitation With Lorcaserin From Analysis of 3 Phase 3 Clinical Trials | Zendy

Neil J. Weissman | Zendy; Matilde Sanchez | Zendy; Gary G. Koch | Zendy; Steven R. Smith | Zendy; William Shanahan | Zendy; Christen M. Anderson | Zendy

Open Access

Echocardiographic Assessment of Cardiac Valvular Regurgitation With Lorcaserin From Analysis of 3 Phase 3 Clinical Trials

Author(s) -

Neil J. Weissman,

Matilde Sanchez,

Gary G. Koch,

Steven R. Smith,

William Shanahan,

Christen M. Anderson

Publication year - 2013

Publication title -

circulation cardiovascular imaging

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.584

H-Index - 99

eISSN - 1942-0080

pISSN - 1941-9651

DOI - 10.1161/circimaging.112.000128

Subject(s) - medicine , placebo , cardiology , odds ratio , dexfenfluramine , confidence interval , body mass index , mitral regurgitation , alternative medicine , receptor , pathology , serotonin , fenfluramine

Lorcaserin is a selective 5-HT2C agonist evaluated for weight management in clinical trials. Echocardiographic monitoring was conducted to test the hypothesis that selective 5-HT2C agonism would avoid valvular heart disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research